Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Phase 2 Completed 64 enrolled Eisai Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the efficacy, safety and tolerability, of AKR-501 (avatrombopag) tablets, as compared to placebo, in the treatment of participants with chronic Idiopathic Thrombocytopenic Purpura (ITP).

Timeline

Start: 2007-02
Primary completion: 2009-01
Completion: 2009-06

Publications

Bussel JB, Kuter DJ, Aledort LM, Kessler CM, Cuker A, Pendergrass KB, Tang S, McIntosh J. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014 Jun 19;123(25):3887-94. doi: 10.1182/blood-2013-07-514398. Epub 2014 May 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Avatrombopag	Small molecule	2.5 mg	Oral
Subject	Avatrombopag	Small molecule	5 mg	Oral
Subject	Avatrombopag	Small molecule	10 mg	Oral
Subject	Avatrombopag	Small molecule	20 mg	Oral

Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Summary

Timeline

Publications

Drugs

Indications